London, United Kingdom

Stephanie Schorge

This inventor holds 3 USPTO granted patents and 4 published patent applications and 2 EPO patents. Top assignee: Ucl Business Plc. Active years: 2019-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stephanie Schorge. Retrieved from https://idiyas.com/inventor/stephanie-schorge-2p1uyhgh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 3 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.3

ph-index = 1


Company Filing History:


Years Active: 2019-2023

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Stephanie Schorge

Introduction

Stephanie Schorge is a prominent inventor based in London, GB, known for her significant contributions to the field of neuroscience. With a total of three patents to her name, she has made remarkable strides in developing innovative treatments for neurological disorders, particularly epilepsy.

Latest Patents

One of her latest patents is focused on expression vectors comprising engineered genes. This invention provides expression vectors, nucleic acids, vector particles, and methods of treatment involving these vector particles, which include an engineered KCNA1 gene encoding an edited Kv1.1 potassium channel. The features of the engineered KCNA1 gene enhance the translation and activity of the Kv1.1 protein, improving the detection of KCNA1 gene expression in a cell. This technology can be utilized in the treatment of epilepsy and similar neurological disorders.

Another notable patent involves the combined use of a vector encoding a modified receptor and its exogenous agonist in the treatment of seizures. This invention outlines methods and materials for treating seizure disorders such as epilepsy. It employs a vector encoding a modified receptor, known as the 'DREADD' receptor, which has a decreased responsiveness to its endogenous activating ligand while retaining or enhancing responsiveness to an exogenous agonist. This innovative approach allows for the modified receptor to be expressed in neurons of a seizure focus in the brain, leading to synaptic silencing or other inhibition.

Career Highlights

Stephanie Schorge is currently associated with UCL Business Plc, where she continues to advance her research and development efforts. Her work has garnered attention for its potential impact on treating neurological conditions, showcasing her dedication to improving patient outcomes.

Collaborations

Throughout her career, Stephanie has collaborated with notable colleagues, including Matthew Charles Walker and Dimitri Michael Kullmann. These partnerships have further enriched her research and contributed to the advancement of innovative solutions in her field.

Conclusion

Stephanie Schorge's innovative work in the realm of neuroscience and her patents reflect her commitment to addressing critical health challenges. Her contributions are paving the way for new treatments that could significantly improve the lives of individuals suffering from neurological disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…